For the Inventor, By the Inventor

Enter assignee name

Shanghai, China

Hutchison Medipharma Limited

USPTO Granted Patents = 37

% Expired Patents = 10.8

CIPO Patents = 3

EPO Patents = 14

Forward Citations = 35

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Wei-Guo Su (24 out of 36 patents)

Guangxiu Dai (13 out of 15 patents)

Wenji Li (9 out of 11 patents)

4. Weihan Zhang (9 out of 25 patents)

5. Zhenping Wu (8 out of 10 patents)

6. Hong Jia (7 out of 13 patents)

7. Wei Deng (7 out of 24 patents)

8. Kun Xiao (6 out of 42 patents)

9. Ling Feng (5 out of 5 patents)

10. Jinshui Li (5 out of 6 patents)

11. Jianguo Ji (4 out of 40 patents)

12. Haibin Yang (4 out of 6 patents)

13. Yongxin Ren (4 out of 10 patents)

14. Yu Cai (3 out of 99 patents)

15. Xiong Li (3 out of 4 patents)

Core Competencies:

Anti-CD47 Antibody

Pyrimidinone Compounds

BTK Inhibitors

Tricyclic Compounds

Crystalline Forms

Pyrrolopyrimidine Compounds

Syk Inhibitors

Imidazopyridazine Compounds

Cycloolefin Compounds

Substituted Piperazines

Triazolopyridines

Pharmaceutical Compositions

37 patents: Sort by Forward Citations

1. 12735500 - ANTI-CD47 ANTIBODY AND USES THEREOF (2026-09-15),

2. 12630554 - PYRIMIDINONE COMPOUNDS AND USES THEREOF (2026-05-19),

3. 12617861 - ANTI-OX40 ANTIBODY AND METHOD OF TREATMENT (2026-05-05),

4. 12559472 - Salts of a compound and the crystalline forms thereof (2026-02-24),

5. 12492210 - Tricyclic compounds and their use (2025-12-09),

6. 12435062 - Amide compounds and uses thereof (2025-10-07),

7. 12234211 - Cycloolefin substituted heteroaromatic compounds and their use (2025-02-25),

8. 12180214 - Crystalline forms of (s)-4-amino-6-((1-(3-chloro-6-phenylimidazo[1,2-b]pyridazine-7-yl)ethyl)amino)pyrimidine-5-carbonitrile as inhibitors of phosphatidylinositol-3-kinase (2024-12-31),

9. 12173008 - Substituted piperazines as BTK inhibitors (2024-12-24),

10. 12134613 - Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof (2024-11-05),

11. 12084441 - Salts of a compound and the crystalline forms thereof (2024-09-10),

12. 12070457 - Substituted pyridines, pyridazines, pyrimidines, and 1,2,3-triazines as bruton's tyrosine kinase inhibitors (2024-08-27),

13. 12030951 - Anti-OX40 antibody and uses thereof (2024-07-09),

14. 11896592 - Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor (2024-02-13),

15. 11655254 - Substituted piperazines as BTK inhibitors (2023-05-23),

Company Overview

Hutchison Medipharma Limited is a biopharmaceutical company based in Shanghai, specializing in the research, development, and commercialization of innovative therapies for cancer and autoimmune diseases. The organization focuses on leveraging advanced technologies and scientific expertise to create novel drug candidates that address unmet medical needs. With a commitment to enhancing patient outcomes, Hutchison Medipharma operates within a dynamic landscape of pharmaceutical innovation, contributing to the global fight against serious health conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

37 Patents

#91 in Shanghai

#857 in China

#18,260 in the World

Shanghai, China

Hutchison Medipharma Limited

Forward Citations = 35

35 inventors:

Wei-Guo Su (24 out of 36 patents)

Guangxiu Dai (13 out of 15 patents)

Wenji Li (9 out of 11 patents)

4. Weihan Zhang (9 out of 25 patents)

5. Zhenping Wu (8 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hutchison Medipharma Limited. Retrieved from https://idiyas.com/company/hutchison-medipharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…